CY1111541T1 - B-2 TREATMENT AGENTS FOR THE TREATMENT OF SKIN CONDUCTIVE MATTER DISEASES - Google Patents

B-2 TREATMENT AGENTS FOR THE TREATMENT OF SKIN CONDUCTIVE MATTER DISEASES

Info

Publication number
CY1111541T1
CY1111541T1 CY20101100919T CY101100919T CY1111541T1 CY 1111541 T1 CY1111541 T1 CY 1111541T1 CY 20101100919 T CY20101100919 T CY 20101100919T CY 101100919 T CY101100919 T CY 101100919T CY 1111541 T1 CY1111541 T1 CY 1111541T1
Authority
CY
Cyprus
Prior art keywords
treatment
skin
conductive matter
skin conductive
adrenoceptor agonist
Prior art date
Application number
CY20101100919T
Other languages
Greek (el)
Inventor
Morten Sloth Weidner
Original Assignee
Astion Development A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Development A/S filed Critical Astion Development A/S
Publication of CY1111541T1 publication Critical patent/CY1111541T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει αποτελεσματικά και ασφαλή φάρμακα για την αγωγή παθήσεων του συνδετικού ιστού του δέρματος, ιδίως σχετιζόμενα με την αγωγή δερματικών μορφών του ερυθηματώδη λύκου. Τα φάρμακα περιλαμβάνουν αγωνιστή β2-αδρενοϋποδοχέα ως θεραπευτικά δραστικό συστατικό. Η εφεύρεση περαιτέρω σχετίζεται με δερματολογικές συνθέσεις χωρίς ιδιότητες ευαισθητοποίησης δέρματος οι οποίες περιέχουν εναντιομερικώς καθαρά ή εμπλουτισμένα R-εναντιομερή του αγωνιστή β2-αδρενοϋποδοχέα.The present invention provides effective and safe medicaments for the treatment of skin connective tissue diseases, especially those related to the treatment of cutaneous forms of erythema lupus. The drugs include a β2-adrenoceptor agonist as a therapeutically active ingredient. The invention further relates to dermatological compositions without skin sensitizing properties containing enantiomerically pure or enriched R-enantiomers of the β2-adrenoceptor agonist.

CY20101100919T 2005-04-13 2010-10-14 B-2 TREATMENT AGENTS FOR THE TREATMENT OF SKIN CONDUCTIVE MATTER DISEASES CY1111541T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500529 2005-04-13
EP06007632A EP1719507B1 (en) 2005-04-13 2006-04-12 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin

Publications (1)

Publication Number Publication Date
CY1111541T1 true CY1111541T1 (en) 2015-08-05

Family

ID=36703472

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100919T CY1111541T1 (en) 2005-04-13 2010-10-14 B-2 TREATMENT AGENTS FOR THE TREATMENT OF SKIN CONDUCTIVE MATTER DISEASES

Country Status (29)

Country Link
US (4) US8426475B2 (en)
EP (1) EP1719507B1 (en)
JP (1) JP5021621B2 (en)
KR (1) KR101355422B1 (en)
CN (1) CN101203214B (en)
AR (1) AR054249A1 (en)
AT (1) ATE473735T1 (en)
AU (1) AU2006233502B2 (en)
BR (1) BRPI0609361A2 (en)
CA (1) CA2604758C (en)
CY (1) CY1111541T1 (en)
DE (1) DE602006015387D1 (en)
DK (1) DK1719507T3 (en)
EA (1) EA016082B1 (en)
ES (1) ES2348920T3 (en)
HK (1) HK1091739A1 (en)
HR (1) HRP20100552T1 (en)
IL (1) IL186491A (en)
MX (1) MX2007012794A (en)
MY (1) MY147864A (en)
NO (1) NO331211B1 (en)
NZ (1) NZ562940A (en)
PL (1) PL1719507T3 (en)
PT (1) PT1719507E (en)
RS (1) RS51464B (en)
SI (1) SI1719507T1 (en)
TW (1) TWI366457B (en)
WO (1) WO2006108424A2 (en)
ZA (1) ZA200708748B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604826D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
WO2008006828A1 (en) * 2006-07-10 2008-01-17 Intervet International B.V. Zilpaterol enantiomer compositions and methods of making and using such compositions
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
GB0805535D0 (en) * 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN102267917B (en) * 2011-06-15 2013-07-31 浙江工业大学 Method for synthesizing methoxyphenamine hydrochloride
CN104284598A (en) * 2012-05-18 2015-01-14 英特维特国际股份有限公司 A method of enhancing performance in broiler chickens
GB2513297A (en) * 2013-03-08 2014-10-29 Univ Leicester Methods
CN104606177B (en) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 Medicinal application of left-handed (R) salbutamol formulation in treatment skin and mucous membrane trauma ulcer
WO2018000098A1 (en) * 2016-06-30 2018-01-04 Cipher Pharmaceuticals Inc. Treatment of inflammatory myopathies
CN106580978A (en) * 2016-11-30 2017-04-26 郑州仁宏医药科技有限公司 Western medicine composition for treating dermatitis, and application of western medicine composition
JP7343500B2 (en) * 2017-08-10 2023-09-12 アブロ ライフ サイエンシーズ，インコーポレーテッド Transdermal drug delivery system
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
WO2021127210A1 (en) 2019-12-18 2021-06-24 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
CN112300237A (en) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 Preparation method and application of seal cholic acid
CN116322671A (en) * 2020-10-09 2023-06-23 Mc2疗法有限公司 Treatment of dermatological disorders
CN116236467B (en) * 2023-02-07 2023-10-27 中国人民解放军总医院 New application of simatron or derivative thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7467B (en) 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferative skin diseases with b2 agonists
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
SU895445A1 (en) * 1980-05-15 1982-01-07 Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова Method of treating cutaneous forms of lupus erythematosus
US4574129A (en) 1984-01-31 1986-03-04 Bristol-Myers Company Topical nonsteroidal anti-inflammatory methods
JPS61154201A (en) 1984-12-26 1986-07-12 Matsushita Electric Ind Co Ltd Dielectric filter
US4699777A (en) 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4980159A (en) 1989-05-23 1990-12-25 Bristol-Myers Squibb Company Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects
RU2092105C1 (en) * 1989-11-20 1997-10-10 Нижегородский научно-исследовательский кожно-венерологический институт Method for dermatologic treatment
DE4014252A1 (en) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed (-)-1-(4'-Amino-3'-cyanophenyl)-2-iso-propyl-amino-ethanol - for treating fatty degeneration, obstructive lung disorders, allergic bronchial asthma, spastic bronchitis and premature labour
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
CA2085366C (en) 1990-07-26 2001-06-12 Samuel J. Tremont Novel polyamines and method for preparation thereof
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
JP3294876B2 (en) 1992-07-20 2002-06-24 トキコ株式会社 Refueling device
WO1995019336A1 (en) 1994-01-12 1995-07-20 Iovis Biomedical And Pharmaceutical Consultants PHENYL ETHANOL AMINE ETHERS AND USES THEREOF AS β-ADRENO-RECEPTOR AGONISTS
JPH07304647A (en) 1994-05-09 1995-11-21 Kao Corp Composition for massage
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
GB9510162D0 (en) * 1995-05-19 1995-07-12 Bouras Elias Compositions for the treatment of skin conditions
JPH09110674A (en) 1995-10-16 1997-04-28 Kao Corp Bathing agent composition
FR2740040B1 (en) 1995-10-23 1997-12-05 Oreal USE OF AT LEAST ONE BETA-ADRENERGIC AGONIST AS A SUBSTANCE P ANTAGONIST
EP0979081A4 (en) 1997-04-30 2003-05-02 Bridge Pharma Inc Composition and methods using an eutomer
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
AU2002248910A1 (en) 2000-11-17 2002-05-27 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrmidines
PT1451154E (en) 2001-12-03 2008-04-21 Wyeth Corp Inhibitors of cytosolic phospholipase a2
SI1496917T1 (en) * 2002-04-19 2006-06-30 Astion Dev As Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
WO2003088997A2 (en) 2002-04-22 2003-10-30 Universiteit Utrecht Holding B.V. Reduction of unwanted immune reactions
WO2003092617A2 (en) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
DE10224888A1 (en) 2002-06-05 2003-12-24 Merck Patent Gmbh pyridazine
TW200422042A (en) * 2002-09-24 2004-11-01 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040229849A1 (en) 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MXPA05006701A (en) * 2002-12-20 2006-03-30 Amgen Inc Asthma and allergic inflammation modulators.
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
WO2004091540A2 (en) * 2003-04-15 2004-10-28 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
JP2009514779A (en) 2003-07-11 2009-04-09 グラクソ グループ リミテッド Pharmaceutical formulation
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ATE497763T1 (en) * 2003-11-21 2011-02-15 Zalicus Inc METHODS AND REAGENTS FOR TREATING INFLAMMATORY DISEASES
EP1725226A2 (en) 2004-03-17 2006-11-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
WO2005102296A2 (en) 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
KR20070083579A (en) 2004-09-07 2007-08-24 소세이 리서치 앤드 디벨롭먼트 리미티드 The treatment of inflammatory disorders and pain

Also Published As

Publication number Publication date
SI1719507T1 (en) 2010-11-30
EA016082B1 (en) 2012-02-28
KR20080005957A (en) 2008-01-15
NO20075527L (en) 2008-01-14
US9907765B2 (en) 2018-03-06
WO2006108424A3 (en) 2006-12-14
TWI366457B (en) 2012-06-21
EP1719507B1 (en) 2010-07-14
PT1719507E (en) 2010-10-21
NO331211B1 (en) 2011-10-31
US20190125699A1 (en) 2019-05-02
ES2348920T3 (en) 2010-12-17
EP1719507A1 (en) 2006-11-08
IL186491A0 (en) 2008-08-07
JP5021621B2 (en) 2012-09-12
HK1091739A1 (en) 2007-01-26
IL186491A (en) 2011-12-29
AR054249A1 (en) 2007-06-13
ZA200708748B (en) 2010-03-31
JP2008535873A (en) 2008-09-04
PL1719507T3 (en) 2010-12-31
ATE473735T1 (en) 2010-07-15
MX2007012794A (en) 2008-02-22
NZ562940A (en) 2010-02-26
BRPI0609361A2 (en) 2010-03-30
CN101203214A (en) 2008-06-18
MY147864A (en) 2013-01-31
US20170157068A1 (en) 2017-06-08
KR101355422B1 (en) 2014-02-06
DK1719507T3 (en) 2010-11-01
CN101203214B (en) 2012-11-21
DE602006015387D1 (en) 2010-08-26
AU2006233502A1 (en) 2006-10-19
TW200719882A (en) 2007-06-01
US20130237607A1 (en) 2013-09-12
CA2604758C (en) 2014-11-25
WO2006108424A2 (en) 2006-10-19
US8426475B2 (en) 2013-04-23
US20060235048A1 (en) 2006-10-19
RS51464B (en) 2011-04-30
EA200702204A1 (en) 2008-04-28
AU2006233502B2 (en) 2011-07-28
CA2604758A1 (en) 2006-10-19
WO2006108424A9 (en) 2007-08-09
HRP20100552T1 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CY1111541T1 (en) B-2 TREATMENT AGENTS FOR THE TREATMENT OF SKIN CONDUCTIVE MATTER DISEASES
CY1111797T1 (en) LOCAL PHARMACEUTICAL FORM FOR IVERMECTIN FOR DERMATOLOGICAL TREATMENT
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
CY1116464T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
CY1116075T1 (en) NEW Liposome Compositions
CY1115719T1 (en) NEW PHARMACEUTICAL COMBINATIONS FOR THE RESPIRATORY DISEASE TREATMENT
CY1115082T1 (en) Substituted 1,3-bisphenylpropane derivatives, preparations and their uses
CY1114863T1 (en) SOLID PREPARATION
CY1105362T1 (en) SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DRUGS
CY1110199T1 (en) PHARMACEUTICAL COMPOSITIONS OF A NEUROACTIVE STEROID AND THEIR USES
CY1115289T1 (en) Methods of Treatment Against Inflammation-Related Illness
CY1113108T1 (en) LEVODOPA BASIC PRODUCT, HIS COMPOSITIONS, AND USES
DOP2002000429A (en) IMIDAZOTRIAZINAS
ATE452129T1 (en) N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
BRPI0414581B8 (en) compound, pharmaceutical composition comprising said compound and use of said compound
CY1106386T1 (en) SUBSTITUTED 3-PYRROLIDINE-INDOLE DERIVATIVES
CY1117326T1 (en) CATEGOLAMINE PRODUCT USEFUL FOR PARKINSON'S DISEASE TREATMENT
CY1114139T1 (en) BUPRENORPHINE PLATE FOR DRUG REPLACEMENT TREATMENT
CY1113003T1 (en) LAQUINIMOD STABLE PREPARATIONS
PA8592301A1 (en) NEW DERIVATIVES OF HETEROCICLIC FLUOROGLYCOSIDS, MEDICINES CONTAINING THESE COMPOUNDS, AND THE USE OF THE SAME
BRPI0412526A (en) compound, use of a compound, pharmaceutical composition, pharmaceutical aerosol formulation, and method for treating a human or animal patient with an anti-inflammatory and / or allergic condition
CY1113039T1 (en) ELECTRIC AND MALONIC TRANS-4- (1R, 3S) -6-CHLORO-3-FINYLINDAN-1-Yl) -1,2,2-TRIMETHYLPIPERAZINE AND USE FOR MEDICINE
CY1106476T1 (en) SUBSTITUTED DIHYDROQUINAZOLINES WITH ANTIVIRAL PROPERTIES
BRPI0510428A (en) methadone topical compositions and processes for using them
CY1106589T1 (en) (S)-2-N-PROPYLAMINO-5-HYDROXYTETRALINE AS A D3-ANTIGENT THERAPEUTIC AGENT